Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Diabetes mellitus type 2 (DMT2) is one of the most frequent glucose metabolism disorders, in which serum glucose concentrations are increased. In most cases, changes in lifestyle and diet are considered as the first step in addressing its therapy. If changes in lifestyle and diet fail, drugs, such as metformin, must be added. Lately, apart from metformin or insulin, the FDA has approved the use of glucagon-like peptide-1 (GLP-1) analogues for children and adolescents. Little is known about their efficacy and safety at this young age. The main aim of this systematic review/meta-analysis was to assess the safety and efficacy of metformin and GLP-1 analogues, exenatide and liraglutide, compared with placebos or other antidiabetic drugs used for DMT2 in children and adolescents. Metformin did not seem to demonstrate pharmacologic superiority, while GLP-1 analogues were found superior to placebos. GLP-1 analogues may be considered a useful alternative for the treatment of DMT2 in children and adolescents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One systematic review of three randomised controlled trials (RCTs) showed that metformin did not lead to significantly better outcomes than glimepiride, placebo, or rosiglitazone for glycaemic control (mean difference [MD] in glycated haemoglobin [HbA 1c ] -0•67%; 95% CI -1•65 to -0•31) or BMI (-0•64 kg/m²; -1•84 to -0•56).56”
From Managing early-onset type 2 diabetes in the individual and at the population level (2025) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 1×
“Certainty Assessment GRADE (grading of recommendations assessment, development, and evaluation) was employed to assess the level of certainty of the results of the studies [14].”
MethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Gastrointestinal symptoms seemed to be most frequent, as those in other studies of adult patients [31,32], and consistent with the known effects of GLP-1 agonists on delaying gastric emptying [33].”
ResultFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Effect of Metformin in Pediatric Patients With Type 2 Diabetes
Jones, K. L., Arslanian, S., Peterokova, V. A., Park, J.-S., & Tomlinson, M. J. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.89 · Cited by 392
TODAY Study Group (2013) · Diabetes Care · doi:10.2337/dc12-2393 · Cited by 288
Healthy overweight/obese youth: early osteosarcopenic obesity features
Stefanaki, C., Peppa, M., Boschiero, D., & Chrousos, G. P. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12659 · Cited by 72
Self-citationTronieri, J. S., Wadden, T. A., Walsh, O., Berkowitz, R. I., Alamuddin, N., & Chao, A. M. (2020) · Behaviour Research and Therapy · doi:10.1016/j.brat.2020.103639 · Cited by 21
Research works printed but not linked: 28
- Khan, 2020, Epidemiology of type 2 diabetes—Global burden of disease and forecasted trends, J. Epidemiol. Glob. Health, 10, 107, 10.2991/jegh.k.191028.001 · DOI · Paper page
- Stefanaki, C., Michos, A., Mastorakos, G., Mantzou, A., Landis, G., Zosi, P., and Bacopoulou, F. (2019). Probiotics in adolescent prediabetes: A pilot RCT on glycemic control and intestinal bacteriome. J. Clin. Med., 8. · DOI
- Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., Ostolaza, H., and Martin, C. (2020). Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci., 21. · DOI · Paper page
- Bacopoulou, 2020, Identifying early abdominal obesity risk in adolescents by telemedicine: A cross-sectional study in Greece, Food Chem. Toxicol. Int. J. Publ. Br. Ind. Biol. Res. Assoc., 144, 111532, 10.1016/j.fct.2020.111532 · DOI
- Pulungan, 2018, Type 2 diabetes mellitus in children and adolescent: An Indonesian perspective, Ann. Pediatric Endocrinol. Metab., 23, 119, 10.6065/apem.2018.23.3.119 · DOI
- Stefanaki, C., Michos, A., Latsios, G., Tousoulis, D., Peppa, M., Zosi, P., Boschiero, D., and Bacopoulou, F. (2020). Sexual dimorphism of heart rate variability in adolescence: A case-control study on depression, anxiety, stress levels, body composition, and heart rate variability in adolescents with impaired fasting glucose. Int. J. Environ. Res. Public Health, 17. · DOI
- Stefanaki, 2016, Prediabetes and adolescence—Trends, causes, effects, and screening, US Endocrinol., 12, 94, 10.17925/USE.2016.12.02.94 · DOI
- Stefanaki, C., Paltoglou, G., Mastorakos, G., and Chrousos, G.P. (2022). Chronic stress and steatosis of muscles, bones, liver, and pancreas—A review. Horm. Res. Paediatr. · DOI
- Bacopoulou, 2018, Disordered eating attitudes and emotional/behavioral adjustment in Greek adolescents, Eat. Weight. Disord., 23, 621, 10.1007/s40519-017-0466-x · DOI
- Wu, 2022, Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021, Diabetes Res. Clin. Pract., 185, 109785, 10.1016/j.diabres.2022.109785 · DOI · Paper page
- Bacha, 2019, FDA approval of GLP-1 receptor agonist (liraglutide) for use in children, Lancet Child Adolesc. Health, 3, 595, 10.1016/S2352-4642(19)30236-6 · DOI
- Soliman, 2020, The clinical application of metformin in children and adolescents: A short update, Acta Bio-Med. Atenei Parm., 91, e2020086
- Matsuura, 2019, Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan, Diabetol Int., 10, 51, 10.1007/s13340-018-0361-3 · DOI
- Gottschalk, 2007, Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: A randomized, single-blind comparative study, Diabetes Care, 30, 790, 10.2337/dc06-1554 · DOI · Paper page
- Klein, 2014, Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: A randomized, double-blind, placebo-controlled trial, Diabetes Technol. Ther., 16, 679, 10.1089/dia.2013.0366 · DOI · Paper page
- Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N. Engl. J. Med., 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
- Guyatt, 2011, GRADE guidelines: 4. Rating the quality of evidence—Study limitations (risk of bias), J. Clin. Epidemiol., 64, 407, 10.1016/j.jclinepi.2010.07.017 · DOI · Paper page
- Higgins, 2011, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 · DOI · Paper page
- Guyatt, 2011, GRADE guidelines 6. Rating the quality of evidence—Imprecision, J. Clin. Epidemiol., 64, 1283, 10.1016/j.jclinepi.2011.01.012 · DOI · Paper page
- Guyatt, 2011, GRADE guidelines: 7. Rating the quality of evidence—Inconsistency, J. Clin. Epidemiol., 64, 1294, 10.1016/j.jclinepi.2011.03.017 · DOI · Paper page
- Guyatt, 2011, GRADE guidelines: 8. Rating the quality of evidence—Indirectness, J. Clin. Epidemiol., 64, 1303, 10.1016/j.jclinepi.2011.04.014 · DOI · Paper page
- Guyatt, 2011, GRADE guidelines: 5. Rating the quality of evidence—Publication bias, J. Clin. Epidemiol., 64, 1277, 10.1016/j.jclinepi.2011.01.011 · DOI · Paper page
- Sanneh, 2012, Clinical effect of Metformin in children and adolescents with type 2 diabetes mellitus: A systematic review and meta-analysis, J. Fam. Community Med., 19, 68, 10.4103/2230-8229.98279 · DOI
- Kuzik, 2015, Evaluating the effects of metformin use on height in children and adolescents: A meta-analysis of randomized clinical trials, JAMA Pediatr., 169, 1032, 10.1001/jamapediatrics.2015.2186 · DOI
- Chadda, 2021, GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis, Obes. Rev., 22, e13177, 10.1111/obr.13177 · DOI · Paper page
- Sun, 2015, Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: A systematic review and network meta-analysis, Diabetes Technol. Ther., 17, 35, 10.1089/dia.2014.0188 · DOI · Paper page
- Monami, 2009, Glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized clinical trials, Eur. J. Endocrinol., 160, 909, 10.1530/EJE-09-0101 · DOI · Paper page
- Temneanu, 2016, Type 2 diabetes mellitus in children and adolescents: A relatively new clinical problem within pediatric practice, J. Med. Life, 9, 235
Cited by
Managing early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
Metadata
- Authors
- Carydias, E., Tasho, A., Kani, C., Bacopoulou, F., Stefanaki, C., & Markantonis, S. L.
- Affiliations
- Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15774 Athens, Greece
- University Research Institute for the Study of Genetic and Malignant Disorders in Childhood, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Venue
- Children
- Publisher
- MDPI AG
- Published
- 2022-10-18
- Volume
- 9
- Issue
- 10
- Pages
- 1572
- ISSN
- 2227-9067
- Cited by
- 5
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2. https://app.cochat.ai/papers/10.3390/children9101572
- The paper
- Carydias, E., Tasho, A., Kani, C., Bacopoulou, F., Stefanaki, C., & Markantonis, S. L. (2022). Systematic Review and Meta-Analysis of the Efficacy and Safety of Metformin and GLP-1 Analogues in Children and Adolescents with Diabetes Mellitus Type 2. Children. https://doi.org/10.3390/children9101572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.